B. Pender

发表

Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure.

D. Maloney, C. Turtle, S. Riddell, 2020, Blood.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

D. Maloney, S. Riddell, M. Jensen, 2016, Cancer Immunology Research.

Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.

S. Heimfeld, B. Wood, D. Maloney, 2015 .

Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes

S. Heimfeld, B. Wood, D. Maloney, 2015 .

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Daniel Li, Jianhong Cao, Xueyan Chen, 2016, The Journal of clinical investigation.

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells

S. Heimfeld, B. Wood, D. Maloney, 2016, Science Translational Medicine.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies.

R. Storb, B. Sandmaier, D. Maloney, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.

M. Bar, D. Maloney, C. Turtle, 2020, Blood.

Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.

D. Maloney, C. Turtle, S. Riddell, 2018 .

in adult B cell ALL patients

S. Heimfeld, B. Wood, D. Maloney, 2016 .

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

D. Maloney, C. Turtle, S. Riddell, 2020 .

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission

D. Maloney, J. Pagel, M. Shadman, 2016, Leukemia & lymphoma.

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

D. Maloney, C. Turtle, S. Riddell, 2018, Blood.

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.